Novel Immunotherapy Clinical Trials for Genitourinary Cancers
Immunotherapy clinical trials are continually bringing promising new treatments to patients with many different types of cancer. These novel cellular therapies fight cancer by harnessing the power of the body’s natural immune system. These research studies are vital not only to helping patients access the immune-based therapies they need but also to accelerate the drug development and approval process. Patients participating in these trials may be among the first to access a potentially effective novel treatment and help to bring that treatment to more patients in the future.
Physicians have the potential to make a significant impact on their patient’s outcomes by discussing and evaluating patients for trials at every stage of their cancer treatment. These trials may not only lead to improved outcomes for patients but also enhanced quality of life.
Below are some of the Genitourinary Oncology immunotherapy trials that are available to qualified candidates.
Kidney Cancer Trials
- Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022), 21691
- Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), 21117
- Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors, 21636
Bladder Cancer Trials
- Phase 3 Study of CG0070 In Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG), 21913
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients, 20943
- Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations, 21460
- Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Unresponsive High-Grade Non-Muscle Invasive Bladder Cancer {NMIBC), 21894
Prostate Cancer Trials
- Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer, 20117
- Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog, 22003
- Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, in patients with therapy refractory metastatic castration-resistant prostate cancer, 21433
At Moffitt, we recognize the importance of clinical trials and we use these studies to develop new and improved ways to prevent, screen for, diagnose and treat a wide array of malignancies. In fact, we’re home to the largest clinical cancer research unit in Florida, with more than 350 active clinical trials. Click the link below to view our entire trial portfolio.
If you'd like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.